SUMMARY Serum from patients with systemic lupus erythematosus (SLE) prevents the proliferative response of normal T cells when stimulated by autologous or allogeneic non-T cells. The abrogation of proliferation in an autologous mixed lymphocyte reaction (AMLR) with SLE serum is associated with a lack of suppressor T cell generation. Fractionation of SLE sera on sucrose gradients reveals an 18-12 S peak of Raji cell binding material. Fractions with an S value of 12 S show inhibitory activity in an AMLR.
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Systemic lupus erythematosus (SLE) is an autoimmune disease characterised both by an excess of circulating immunoglobulins' and by the production of antibodies normally immunogenically quiescent. Antigens abnormally recognised in SLE include nuclear proteins,2 nucleic acids,3 ,8-2 microglobulin,4 and T lymphocyte surface molecules.5
Normally the production of antibodies by B lymphocytes is influenced by the activity of T lymphocytes. Helper T cells (Th) increase B cell antibody production, while suppressor T cells (Ts) reduce it. The abnormal antibody production in SLE may therefore reflect an intrinsic B cell defect, malfunctioning of T cell control of B cell activity, or both. We report here that lupus sera contain an activity which inhibits the generation of Ts cells in normal donors.
The autologous mixed lymphocyte reaction (AMLR) is a proliferative response of normal T cells when stimulated in vitro by autologous non-T cells.6 In this response T cells are generated which suppress the proliferative and cytotoxic responses of fresh T cells7 as well as inhibiting B cell antibody production. For example, AMLR primed T cells suppress the proliferation of fresh T cells stimulated by either autologous or allogeneic non-T cells. Antibody pro-duction in vitro, induced both polyclonally by mitogen and specifically by antigen, is also suppressed by AMLR primed T cells.8 Cells (Fig. 2) .
The effect ofSLE serum on the normal A MLR and allogeneic MLR. The same SLE sera with differing levels of Raji cell binding material (RBM) were added to both an AMLR and an allogeneic MLR using responder E+NA cells from the same normal donor. In NHS both autologous and allogeneic responses showed marked peaks of IUDR incorporation, reaching a maximum at day 5-6. All the SLE sera essentially completely inhibited the proliferation of the responder E+NA cells in the AMLR. However, the same SLE sera reduced the response of the responder E + NA to allogeneic stimulation but not to the same extent as in the AMLR (Fig. 3) .
SLE serum was incubated overnight with or without Raji cells before addition to a normal AMLR or allogeneic MLR (Fig. 4) Allogeneic MLR using cells from normal donors in 10 % (HI) SLE serum (patient no. 5, 0-0); 10 % (HI) Raji absorbed SLE serum (patient no. 5, rn-).
or sham-absorbed SLE serum as described above, proliferative responses within the normal range were revealed after absorption with Raji cells. Normally the maximum incorporation of IUDR was greater in the allogeneic than the autologous MLR. In Fig. 4 the autologous and allogeneic responses which had roughly equal peak incorporation have been chosen so as to demonstrate the differential inhibitory effect of the SLE sera.
Inhibition of suppressor cell generation in the AMLR in SLE serum. An AMLR with cells from a normal donor was set up in NHS and an SLE serum and pulsed daily with '25IUDR. As described above, the response in SLE serum did not show any increased incorporation over that of the cultured but unstimulated E+NA cells, while the AMLR in NHS showed significant uptake with a peak incorporation at day 6 (5800 cpm). Viable cells from the unstimulated cultures and from stimulated cultures in NHS and SLE serum were recoverd by centrifugation on Ficoll/Hypaque. The recovered cells were added, in the numbers shown, to a second fresh AMLR in NHS using cells from the same normal donor. Cultures were pulsed daily with 125IUDR (Fig. 5 ).
In the presence of cultured but unstimulated E+NA cells the fresh AMLR showed significant of the fresh AMLR to which they were added (data not shown). In the presence of T cells recovered from the AMLR in SLE serum 125IUDR incorporation rose to reach a maximum on day 6 of the response. There was no accelerated peak on day 3, nor was the incorporation on day 6 significantly lower than in AMLR cultures containing the same number of cultured, unstimulated T cells. Mitomycin C inactivation of AMLR primed cells was without effect on the magnitude and kinetics of the proliferative response The addition offractions from the same SLE gradient to an AMLR in NHS using cells from a normal donor. The results are expressed as a percentage of the day 6 response of the control AMLR cultures with no fractions added. BSA was used as a protein control. 
Discussion
This paper shows, firstly, that sera from patients with active SLE inhibit the proliferative response by T cells from normal donors when stimulated by either autologous or allogeneic non-T cells. We show also that the abrogation by SLE sera of proliferation in the AMLR is associated with a lack of suppressor T cell generation.
Inhibition of the allogeneic MLR by SLE sera has already been reported.5 All the sera we have studied (total of 38 serum samples from 18 patients) inhibit the AMLR more profoundly than the allogeneic reaction. In some cases individual SLE sera, without effect in the proliferative response to alloantigen, can inhibit the AMLR completely.
These serum-mediated inhibitory effects occur independently of the treatment received by individual patients ( (Fig. 5) .
Cells from SLE patients are also deficient in the suppressor response to mitogen,9 and this deficiency is exaggerated if the response is performed in autologous serum."1 SLE serum has been reported to prevent the in vitro generation of suppressor cells in normals as opposed to inhibiting the function of Ts once activated.20 Our data may well support this observation.
Fractionation of SLE sera on sucrose gradients, with measurement of RBM in individual fractions, reveals on 8-12 S peak of material in all SLE sera investigated (Fig. 6, upper section) . Addition of these fractions to an AMLR in NHS shows the inhibitory activity to have an S value of -12S (Fig. 6, lower section). Although 19 S IgM anti-T cell antibodies have been well described in the sera of patients with SLE,2' the fractionation study would suggest that they are not responsible for the inhibitory effects reported here. Further characterisation of the inhibitory factor is in progress.
It has been suggested that anti-T cell antibodies are responsible for the suppressor T cell deficiency in NZB mice,22 a classical animal model of SLE.23 Recent evidence in the mouse, however, suggests that T cell defects can exist independently of any serological effect.24 Anti-T cell antibodies have also been described in human SLE, as well as cellular defects in suppressor T cell generation in the AMLR and by mitogen. The data presented here suggest that any inherent cellular dysfunction may be reinforced by serum-borne factors. 
